🇺🇸 Epirubicin+Cyclophosphamide in United States

28 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Aseptic Necrosis Bone — 5 reports (17.86%)
  2. Osteonecrosis — 5 reports (17.86%)
  3. Impaired Healing — 3 reports (10.71%)
  4. Pain In Jaw — 3 reports (10.71%)
  5. Bone Disorder — 2 reports (7.14%)
  6. Osteolysis — 2 reports (7.14%)
  7. Pain — 2 reports (7.14%)
  8. Tooth Abscess — 2 reports (7.14%)
  9. Tooth Extraction — 2 reports (7.14%)
  10. Weight Decreased — 2 reports (7.14%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Epirubicin+Cyclophosphamide approved in United States?

Epirubicin+Cyclophosphamide does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Epirubicin+Cyclophosphamide in United States?

The First Affiliated Hospital with Nanjing Medical University is the originator. The local marketing authorisation holder may differ — check the official source linked above.